双成药业(002693) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥81,485,154.92, representing an increase of 11.27% compared to ¥73,230,987.79 in the same period last year[2] - Net profit attributable to shareholders reached ¥4,505,619.82, a significant increase of 517.11% from ¥730,119.24 year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥1,599,812.27, up 125.66% from a loss of ¥6,233,934.62 in the previous year[2] - Basic earnings per share increased to ¥0.0110, reflecting a growth of 511.11% compared to ¥0.0018 in the same period last year[2] - Total operating revenue for Q1 2023 was CNY 81,485,154.92, an increase of 11.5% compared to CNY 73,230,987.79 in the same period last year[31] - Net profit for Q1 2023 was CNY 103,484.98, a significant recovery from a net loss of CNY 2,492,564.24 in the previous year[32] - Basic and diluted earnings per share for Q1 2023 were CNY 0.0110, compared to CNY 0.0018 in the same period last year, representing a growth of 511.1%[32] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥19,881,051.09, a decline of 30.07% compared to -¥15,284,942.57 in the same period last year[2] - The company reported a decrease in cash and cash equivalents from RMB 12,196,777.95 at the beginning of the year to RMB 5,920,315.43 at the end of the quarter[26] - The company's total current assets decreased from RMB 252,394,374.44 at the beginning of the year to RMB 241,151,591.67 at the end of the quarter[28] - The total cash and cash equivalents at the end of the period were 5,920,315.43 CNY, down from 14,375,610.63 CNY in the previous period, indicating a decrease in liquidity[34] - The total cash outflow from operating activities was 100,818,167.95 CNY, compared to 95,615,637.78 CNY in the previous period, indicating higher operational costs[33] Investment and Financing Activities - The company reported a 129.10% increase in cash received from investment recoveries, indicating improved cash flow management[9] - Total cash inflow from investment activities was 150,408,649.83 CNY, significantly higher than 63,667,129.39 CNY in the previous period, reflecting increased investment recovery[34] - The net cash flow from investment activities improved to 20,985,778.54 CNY, compared to -41,225,949.49 CNY in the previous period, showing a positive turnaround[34] - Cash inflow from financing activities decreased to 4,392,700.00 CNY from 51,708,400.00 CNY in the previous period, indicating reduced borrowing[34] - The net cash flow from financing activities was -1,979,509.71 CNY, a significant drop from 49,291,851.39 CNY in the previous period, highlighting challenges in financing[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥890,784,444.32, a decrease of 2.22% from ¥911,018,789.08 at the end of the previous year[2] - The company's total liabilities decreased to CNY 309,027,615.64 from CNY 330,076,360.29 at the beginning of the year, a reduction of approximately 6.4%[30] - The total equity attributable to shareholders of the parent company increased to CNY 518,764,494.90 from CNY 513,547,960.18, marking a growth of 1.4%[30] - The company's total non-current assets decreased from RMB 658,624,414.64 at the beginning of the year to RMB 649,632,852.65 at the end of the quarter[28] Research and Development - Research and development expenses grew by 46.39% year-on-year, indicating increased investment in R&D projects[7] - Research and development expenses rose to CNY 2,589,268.35, up 46.5% from CNY 1,768,762.68 in the previous year[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 48,474[11] - Hainan Shuangcheng Investment Co., Ltd. holds 32.92% of shares, with 136,516,546 shares pledged[11] - HSP Investment Holdings Limited owns 15.58% of shares, totaling 64,599,379 shares, with 16,210,000 shares pledged[11] - The top ten shareholders include both domestic and foreign entities, with significant shareholding by Hainan Shuangcheng Investment Co., Ltd. and HSP Investment Holdings Limited[11] - The company has implemented a stock option and restricted stock incentive plan, granting 7 million restricted shares at RMB 1.91 per share and 7 million stock options at RMB 3.82 per option[13] Strategic Agreements - The company signed a product rights transfer agreement with Chongqing Laimei Pharmaceutical Co., Ltd. and Hangzhou Boying Health Technology Co., Ltd. for a total contract amount of RMB 32 million, acquiring all tangible and intangible assets related to the acetate triptorelin injection in China[20] - The company entered into a licensing and supply agreement with Meitheal Pharmaceuticals, Inc. and Hong Kong King-Friend Industrial Co., Ltd. for the exclusive rights to develop and produce paclitaxel injection (albumin-bound) in the U.S., with a total milestone payment of USD 6 million, of which USD 3 million has been received[23] Employee Compensation and Incentives - The company reported a decrease in employee compensation payable from CNY 8,596,015.63 to CNY 5,860,557.02, a decline of 31.5%[30] - The company’s incentive plan aligns with its strategic goals to enhance employee motivation and retention[19] Audit and Reliability - The first quarter report was not audited, which may affect the reliability of the financial data presented[35] - The company did not report any new product launches or technological advancements during this quarter[36]